汉防己甲素对肝硬化患者血清透明质酸及Ⅲ型前胶原肽含量的影响

FFFECTS OF TETRANDRINE ON SERUM HYALURONATE AND TYPE Ⅲ PROOLLAGEN PEPTIDE IN PATIENTS WITH ClRRHOSIS

采用口服汉防已甲素抗肝纤维化治疗,并以肝泰乐保肝治疗作对照,观察治疗前后肝硬化患者血清 HA.PⅡP,肝组织学及肝肾功能的变化,随访18个月。结果血清 HA(404.8±140.0比588.0±181.2nmol/L),PⅢP(19.4±5.5比31.8±10.9nmol/L)的含量及肝活组织免疫组化染色Ⅰ、Ⅱ型胶原与治疗前相比有显著差异(P<0.05～0.01),与对照组(HA 539.8±150.2比586.9±179.8nmol/L、PⅢP25.9±8.4比29.0±9.4nmol/L)相比较仍有统计学意义(P<0.01)。

54 patients with cirrhosis were given tetrandrine orally as an anti-fibrotic agent.21 patients were given glucurolactone as control group.All of the patients were followed up for 18 months.Serum hyaluronate(HA) and type Ⅲ procollagen peptiae(PⅢP)were measured before and after the treatment.The liver and renal functions and liver histology were examined at the same time.The results showed that serum levels of HA(404.8±140.0 vs 588.0±181.2 nmol/L)and PⅢP(19,4± 5.4 vs 31.8±10.9 nmol/L)were lowered significantly(P<0.01～0.001).The liver and renal functions improved(P<0.05～0.01).Immunohistochemical staining for type Ⅰ and Ⅲ collagen were decreased remarkedly compared with pretreatment.The levels of serum HA(539.8±150.2 vs 586.9±179.8 nmol/L).PⅢP (25.9±8.4. vs 29.0±9.4 nmol/L)and liver type I and Ⅲ collagen were lower significantly in tetrandrine-treated group than in control group(P<0.05～0.01).